Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.48 |
| ▸ | CDK2 | P24941 | 6/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447013 | 0.90 | CCNA2 (0.52) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5459347 | 0.89 | AURKA (0.61) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5449349 | 0.86 | AURKA (0.51) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454239 | 0.85 | AURKA (0.51) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5451393 | 0.83 | NFKB1 (0.44) | AURKACCNA2CDK2CCNA1 | |
| SCHEMBL5495916 | 0.82 | AURKA (0.55) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454345 | 0.81 | AURKA (0.53) | AURKACCNA2CDK2CCNA1BTK | |
| SCHEMBL5454355 | 0.80 | AURKA (0.51) | AURKACCNA2CDK2CCNA1BTK | |
| SCHEMBL5446945 | 0.80 | AURKA (0.61) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5456582 | 0.80 | AURKA (0.52) | AURKACCNA2CDK2CCNA1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | AURKA 179/4885CCNA2 1123/4885CDK2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.